Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis

Nimotuzumab is a blocking monoclonal antibody against epidermal growth factor receptor (EGFR). However, little is known about the safety and preliminary efficacy of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced NPC patients. A total of 42 patients diagnosed between 2011...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhi-gang, Zhao, Yu, Tang, Jiao, Zhou, Yu-juan, Yang, Wen-juan, Qiu, Yan-fang, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029712/
https://www.ncbi.nlm.nih.gov/pubmed/27016412
http://dx.doi.org/10.18632/oncotarget.8225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029712/
https://www.ncbi.nlm.nih.gov/pubmed/27016412
http://dx.doi.org/10.18632/oncotarget.8225

Ejemplares similares